Harrow announces 52-Week data from VEVYE ESSENCE-2 open-label extension study

Harrow announces results from its ESSENCE-2 open-label extension OLE clinical study for VEVYE or cyclosporine ophthalmic solution ,0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease DED. ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE-2 study, receiving VEVYE in each eye twice a day for 52 weeks. The one-year study results, published in Cornea, demonstrated VEVYE’s sustained safety and efficacy in treating the signs and symptoms of DED, underscoring its value in managing this chronic condition. Key findings include: Statistically significant improvements in all prespecified efficacy endpoints compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously and symptomatology improvement